Previous 10 | Next 10 |
A question that comes up a lot about mRNA vaccines is what happens at the cellular level after you're injected with one. The mechanism of any such vaccine is to cause cells to produce a viral protein antigen, but which cells actually do this? Let's dive into some details. But whil...
The biotechnology sector has been the focus of investors since the outbreak of the COVID-19 pandemic. Initially, all eyes were on accurate COVID-19 testing, followed by an anxious wait for vaccines. The speedy development of coronavirus vaccines then opened eyes to possible cures for other ra...
Alnylam Pharmaceutical ([[ALNY]] +1.6%) sees interim Q4 revenues from Onpattro (patisiran) of ~$90M and $306M in FY2020. At year-end, over 1,350 patients were receiving treatment.Givlaari (givosiran) Q4 and FY 2020 sales is expected at ~$22M and $55M, respectively.Following European Medicines...
2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...
– New 5-Year Strategy Represents Alnylam’s Commitment to Delivering Transformative Rare and Prevalent Disease Medicines for Patients Around the World Through Sustainable Innovation and Exceptional Financial Performance Driving Profitability – – In A...
The announcement of positive topline data by Alnylam Pharmaceuticals (ALNY) for vutrisiran ‘doesn't deflect disruptive potential of NTLA-2001’ of Intellia Therapeutics (NTLA) in hATTR amyloidosis with polyneuropathy, the analysts from Baird write in a research note.However, ahea...
Alnylam announced that the HELIOS-A Phase III study of vutrisiran for hATTR-polyneuropathy achieved all of its primary and secondary endpoints. Vutrisiran's improved dosing profile and tolerability are important positives, but the real value-driver is the HELIOS-B study in ATTR-cardio...
After Alnylam Pharmaceuticals ([[ALNY]] +7.6%) announced positive clinical trial data today for vutrisiran in a Phase 3 study for the treatment of transthyretin-mediated (“ATTR”) amyloidosis, Wall Street analysts are weighing in on the company’s prospects.With A...
Alnylam Pharmaceuticals (ALNY) up 4% in premarket after announcing topline results from HELIOS-A Phase 3 study evaluating vutrisiran in patients with hATTR amyloidosis with polyneuropathy (damage to multiple peripheral nerves).Vutrisiran met primary and all secondary endpoints at 9 ...
– Vutrisiran Met Primary and All Secondary Endpoints at 9 Months, with Statistically Significant Improvements in Progression of Neuropathy, Quality of Life (QOL), and Gait Speed, Relative to Placebo – – Majority of Patients Showed Reversal of Disease Manif...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...